2B70:F:F-iShares NASDAQ US Biotechnology UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 6.269

Change

-0.02 (-0.25)%

Market Cap

USD 0.52B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict
Created with Highstock 5.0.6

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
2B70:F
Relative Returns (From:    To: 2025-01-29 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0ZC:F Zscaler Inc

+3.85 (+1.91%)

USD 37.92B
BSND:F Danone SA

+0.30 (+2.33%)

USD 33.83B
MCH1:F C.G.E.MICHEL.UNSP.ADR 1/2

-0.20 (-1.20%)

USD 14.90B
6FHA:F Futu Holdings Limited

-6.00 (-5.00%)

USD 12.31B
63TA:F Tencent Music Entertainment Gr..

N/A

USD 10.16B
IIO:F Iida Group Holdings Co. Ltd.

-0.10 (-0.70%)

USD 5.83B
NZTA:F Spark New Zealand Ltd

N/A

USD 5.12B
FPE4:F Fuchs Petrolub SE

+0.10 (+0.85%)

USD 4.94B
7LB:F Lotus Bakeries NV

+40.00 (+0.44%)

USD 4.51B
4B1:F China Bohai Bank Co. Ltd.

N/A

USD 3.83B

ETFs Containing 2B70:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.76% 68% D+ 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.76% 68% D+ 59% D-
Trailing 12 Months  
Capital Gain 6.13% 42% F 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.13% 39% F 45% F
Trailing 5 Years  
Capital Gain 38.19% 62% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.19% 61% D- 47% F
Average Annual (5 Year Horizon)  
Capital Gain 4.97% 51% F 53% F
Dividend Return 4.97% 48% F 46% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.28% 51% F 84% B
Risk Adjusted Return 37.42% 46% F 57% F
Market Capitalization 0.52B 64% D 49% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.